We believe that expert statistical input has the power to shape the future of clinical development: de-risking portfolios, accelerating timelines, and increasing the probability of success.
With the use of a promising zone approach Cytel ‘de-risked’ the study and improved transparency. The client obtained external investment with a flexible, novel financing structure that was linked to interim results in a staged approach.
Cytel designed and developed adaptive trial simulation software to predict probable outcomes of a variety of study approach scenarios. The adaptive design enabled the sponsor to lower the economic risk and increase development options.